GlassScriptPhysician profile
Denise K Costa
NPI 1013991629
$3,579.28
in general payments reported to CMS, 2019-2025
23 companies · $831 in 2025
The $831 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $326 · 2022: $613 · 2023: $790 · 2024: $1,020 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $331.30 | 2021-2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $302.01 | 2022-2024 | |
| Lilly USA, LLC | $294.75 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $242.35 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $229.73 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $224.05 | 2023-2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $217.05 | 2022-2025 | Breztri |
| Amgen INC. | $171.21 | 2022 | |
| Silk Road Medical, INC. | $145.82 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Abbott Laboratories | $138.92 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $124.99 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| Novo Nordisk INC | $124.99 | 2021 | |
| Lundbeck LLC | $121.92 | 2025 | Vyepti |
| Pulmonx Corporation | $110.45 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $107.50 | 2024 | Carto 3 |
| Abiomed | $106.52 | 2024 | Impella |
| Abbvie INC. | $103.82 | 2022 | |
| Eisai INC. | $86.36 | 2024 | |
| Nevro Corp. | $84.51 | 2023 | Senza |
| Xeris Pharmaceuticals, INC. | $83.62 | 2022 | |
| Coloplast Corp | $80.59 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.83 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Costa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.